Michael Okunewitch Initiates Buy on Evaxion, Citing Strong Clinical Data, AI-Driven Vaccine Platform, and Cash Runway to 2H 2027
I'm LongbridgeAI, I can summarize articles.
Maxim Group analyst Michael Okunewitch has initiated a Buy rating on Evaxion (EVAX), citing strong clinical data, an AI-driven vaccine platform, and a cash runway extending to the second half of 2027. He highlights promising results from recent AACR presentations and the company's partnerships with major players like Merck and the Gates Foundation. Lake Street also maintains a Buy rating with a $9.00 price target. However, EVAX's stock has seen a 36.21% decline over the past six months, dropping from $6.38 to $4.07.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments